Osteoporosis guidance re-evaluated by NICE30th March 2009
The National Institute for Health and Clinical Excellence has said it will be releasing "its economic model to consultees" as part of its re-evaluation of its osteoporosis guidance.
NICE had been taken to the High Court by Servier Laboratories because of its guidance on the use of the drug Protelos. It is estimated that up to 15% of women with the condition - who cannot take biosphosphates - could be in danger of fractures. The current guidance will remain in place until the re-evaluation is finished.
Share this page
There are no comments for this article, be the first to comment!
Post your comment
Only registered users can comment. Fill in your e-mail address for quick registration.
Title: Osteoporosis guidance re-evaluated by NICE
Author: Jess Laurence
Article Id: 10776
Date Added: 30th Mar 2009